CVRx, Inc. announced that Chief Financial Officer Jared Oasheim will step down from his role to pursue other professional opportunities. Oasheim will remain with the company until a successor is appointed and will stay available as an advisor through February 2027 to ensure a seamless transition. The company has initiated a search to identify its next Chief Financial Officer.

Kevin Hykes, President and Chief Executive Officer of CVRx, highlighted Oasheim's tenure since 2015. Hykes credited Oasheim with leading the company through its initial public offering and building the finance organization that supports current commercial growth.

Oasheim noted that taking the company public and establishing its financial foundation were career highlights. He expressed commitment to a smooth transition and confidence in the company's continued momentum.

Separately, CVRx executives are scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The presentation is set for Wednesday, June 10, 2026, at 8:00 a.m. (ET) in Miami. A live webcast will be available at ir.cvrx.com, with an archived version accessible afterward for a limited time.

CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases. Its primary product, Barostim, is an FDA-approved implantable device designed to improve heart failure symptoms by delivering electrical pulses to baroreceptors in the carotid artery.